Clinical-grade antibodies Exonbio specializes in recombinant antibodies and proteins with SPIN technology for rabbit rrMAb development, presenting an opportunity to position them as a source of high-affinity reagents for diagnostics and therapeutic R&D partners.

COVID-19 lineage Active in SARS-CoV-2 spike monoclonal antibodies for antigen assays and therapeutics, suggesting potential upsell to ongoing infectious disease testing, surveillance programs, and pandemic preparedness collaborations.

Small but nimble With a lean team and revenue in the 1–10M range, Exonbio may be receptive to cost-effective collaborations, CDMO partnerships, and fast-turnaround pilot projects to validate new antibodies or proteins.

Strategic partnerships Recent press indicates emphasis on high-affinity spike antibodies; potential opportunities include co-development, licensing, or contract manufacturing to expand product lines and accelerate market reach.

Digital and e‑commerce readiness Presence on a modern tech stack and WooCommerce integration implies readiness for direct-to-biz ordering or partner portals; leverage for streamlined procurement, sublicensing, or joint marketing campaigns.